It's pretty unusual for guidelines to change based on one study.
But the quality of that data has led to the guidelines being changed
-- obviously repositioning dual bronchodilation ahead of ICS/LABAs in the treatment of COPD.
１つの治験結果だけでガイドラインが変更されるなんてとっても珍しい事だとVecturaのCEOもおっしゃってますね
この部分は私も読んでませんでした（chiさんに感謝
***
It's pretty unusual for guidelines to change based on one study.
But the quality of that data has led to the guidelines being changed
-- obviously repositioning dual bronchodilation ahead of ICS/LABAs in the treatment of COPD.
１つの治験結果だけでガイドラインが変更されるなんてとっても珍しい事だとVecturaのCEOもおっしゃってますね
この部分は私も読んでませんでした（chiさんに感謝